Abstract
As men age, there is an increase in the frequency of pathologic diseases affecting the genitourinary tract. Most notable among these changes are the rising prevalence of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). The pathogenesis of these conditions seems to be multifactorial and includes age-related changes in the nervous system and neuroregulatory factors, such as nitric oxide and RhoA/Rho-kinase. Various pharmacologic agents that target these pathways, such as α-blockers and PDE-5is, underscore the contribution of neuroregulatory factors on the development of LUTS/BPH and ED.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Aging / physiology*
-
Carbolines / therapeutic use
-
Disease Progression
-
Erectile Dysfunction / drug therapy
-
Erectile Dysfunction / epidemiology
-
Erectile Dysfunction / physiopathology*
-
Humans
-
Imidazoles / therapeutic use
-
Lower Urinary Tract Symptoms / epidemiology
-
Lower Urinary Tract Symptoms / physiopathology*
-
Lower Urinary Tract Symptoms / therapy
-
Male
-
Men's Health
-
Middle Aged
-
Neurotransmitter Agents / therapeutic use
-
Piperazines / therapeutic use
-
Prognosis
-
Prostatic Hyperplasia / drug therapy
-
Prostatic Hyperplasia / epidemiology
-
Prostatic Hyperplasia / physiopathology*
-
Purines / therapeutic use
-
Receptors, Neurotransmitter / drug effects
-
Receptors, Neurotransmitter / metabolism*
-
Risk Assessment
-
Sildenafil Citrate
-
Sulfones / therapeutic use
-
Tadalafil
-
Triazines / therapeutic use
-
Vardenafil Dihydrochloride
Substances
-
Carbolines
-
Imidazoles
-
Neurotransmitter Agents
-
Piperazines
-
Purines
-
Receptors, Neurotransmitter
-
Sulfones
-
Triazines
-
Vardenafil Dihydrochloride
-
Tadalafil
-
Sildenafil Citrate